Valsartan in Elderly Isolated Systolic Hypertension (VALISH) study: Rationale and design

Hypertension Research

Volumn 27, Issue 9, 2004, Pages 657-661

  Ogihara, Toshio ^a   Saruta, Takao ^b   Matsuoka, Hiroaki ^c   Shimamoto, Kazuaki ^d   Fujita, Toshiro ^e   Shimada, Kazuyuki ^f   Imai, Yutaka ^g   Nishigaki, Masaru ^h   Kikuchi, Kenjiro ⁱ   Ito, Sadayoshi ⁱ   Etoh, Tanenao ⁱ   Imaizumi, Tutomu ⁱ   Kimura, Genjiro ⁱ   Takishita, Shuichi ⁱ   Ueshima, Hirotsugu ⁱ   Rakugi, Hiromi ⁱ  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c DOKKYO MEDICAL UNIVERSITY   (Japan)

^d SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f JICHI MEDICAL UNIVERSITY   (Japan)

^g TOHOKU UNIVERSITY   (Japan)

^h NIHON FUKUSHI UNIVERSITY   (Japan)

ⁱ NONE

Author keywords

Cardiovascular events; Clinical trial; Isolated systolic hypertension; Valsartan

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM ANTAGONIST; DIURETIC AGENT; VALSARTAN;

ADULT; AGE; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ELDERLY CARE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; JAPAN; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MORBIDITY; MORTALITY; MULTICENTER STUDY; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; RESEARCH ETHICS; SAMPLE SIZE; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; TREATMENT OUTCOME;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HUMANS; HYPERTENSION; INCIDENCE; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; TETRAZOLES; VALINE;

EID: 20844457604     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.27.657     Document Type: Article

References (26)

1. Kannel WB: Historical perspectives on the relative contributions of diastolic and systolic blood pressure elevation to cardiovascular risk profile. Am Heart J 1999; 138: S205-S210.
2. Staessen JA, Gasowski J, Wang JG, et al: Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trails. Lancet 2000; 355: 865-872.
3. Franklin SS, Khan SA, Wong ND, et al: Is pulse pressure useful in predicting risk for coronary heart disease?: the Framingham heart study. Circulation 1999; 100: 354-360.
4. Neal B, MacMahon S, Chapman N, Blood Pressure Lowering Treatment Trials' Collaboration: Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs: result of prospectively designed over views of randomised trails. Lancet 2000; 355: 1955-1964.
5. Staessen JA, Wang JG, Thijs I: Cardiovascular protection and blood pressure reduction; a meta-analysis. Lancet 2001; 358: 1305-1315.
6. Collins R, Peto R, MacMahon S, et al: Blood pressure, stroke, and coronary heart disease: part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
7. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP): SHEP Cooperative Research Group. JAMA 1991; 265 3255-3264.
8. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO: Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281-1285.
9. The GLANT Study Group: A 12-month comparison of ACE inhibitor and Ca antagonist therapy in mild to moderate essential hypertension: the GLANT study. Hypertens Res 1995; 18: 235-244.
10. Ogihara T, on behalf of the PATE-Hypertension Study Group in Japan: Practitioner's trial on the efficacy of antihypertensive treatment in the elderly hypertension (the PATE-Hypertension Study) in Japn. Am J Hypertens 2000; 13: 461-467.
11. Chobanian AV, Bakris GL, Black HR, et al: The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
12. Guideline Committee: 2003 European Society of Hypertension - European Society of Cardiology guideline for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
13. Japanese Society of Hypertension Guidelines Subcommittee for the Management of Hypertension: Guidelines for the management of hypertension for general practitioners: edition 2000 (JSH 2000). Hypertens Res 2001; 24: 613-634.
14. 1-receptor subtype. Br J Pharmacol 1993; 110: 761-771.
15. 1 receptors. Regul Peptides 1995; 59: 303-311.
16. Fogari R, Zoppi A, Mugellini A, et al: Comparative efficacy of losartan and valsartan in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring. Curr Ther Res 1999; 60: 195-206.
17. Corea L, Cardoni O, Fogari R, et al: Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension. Clin Pharmacol Ther 1996; 60: 341-346.
18. Malacco E, Vari N, Capuano V, et al: A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst Study. Clin Ther 2003; 25: 2765-2780.
19. Kannel WB: Histolic perspectives on the relative contributions of diastolic and systolic blood pressure elevation to cardiovascular risk profile. Am Heart J 1999; 138 (3 part 2): 205-210.
20. Yui Y, Sumiyoshi T, Kodama K, et al: Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan multiple investigation for cardiovascular diseases-B (JMIC-B) randomized trial. Hypertens Res 2004; 27: 181-191.
21. August P: Initial treatment of hypertension. N Engl J Med 2003; 348: 610-617.
22. The ALLHAT Officers and Coordination for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertension patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2003; 288 2981-2997.
23. Hansson L, Zanchetti A, Carruthers SG, et al: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial: HOT Study Group. Lancet 1998; 351: 1755-1762.
24. Ogihara T, Morimoto S, Okaishi K, et al: Questionnaire survey on the Japanese guidelines for treatment of hypertension in the elderly: 1999 revised version. Hypertens Res 2002; 25: 69-75.
25. PROGRESS Collaborative Group: Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041.
26. Fukui T, Rahman M, Hayashi K, et al: Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods. Hypertens Res 2003; 26: 979-990.